October 18, 2017

Critical Outcome Closes Second Tranche of $2 Million Private Placement

October 11, 2017

Critical Outcome Technologies Announces First Patient Dosed in Phase 1 Trial of COTI-2 in Head and Neck Squamous Cell Carcinoma

September 29, 2017

Critical Outcome Reports Fiscal 2018 First Quarter Results

September 20, 2017

Critical Outcome Closes $1.5 Million Private Placement

September 7, 2017

Critical Outcome Technologies Announces CEO to Co-Chair Global Genes Rare Partnering & Investor Forum

September 5, 2017

COTI to Present at Rodman and Renshaw

August 28, 2017

COTI Announces Fourth Quarter and Full Year 2017 Financial Results

August 14, 2017

Critical Outcome Technologies Completes Phase 1 Dose Escalation Portion of COTI-2 Trial in Gynecological Malignancies

June 28, 2017

Critical Outcome Technologies Addresses Recent Trading Activity

June 23, 2017

Critical Outcome Technologies Announces Share Consolidation

May 11, 2017

Critical Outcome Technologies Appoints Experienced Biotech Leader as Chief Scientific Officer

March 17, 2017

Critical Outcome Technologies Announces CEO to Moderate Rare Diseases Panel at BIO-Europe

March 16, 2017

Critical Outcome Technologies Reports Third Quarter Financial and Operating Results for Fiscal Year 2017

February 1, 2017

Critical Outcome Technologies Announces Departure of Chief Scientific Officer

January 17, 2017

Critical Outcome Technologies to be a Panelist and Presenter at Cantech Investment Conference in Toronto

January 10, 2017

Critical Outcome Advances to Fourth Cohort in Phase 1 Study of COTI-2 in Gynecologic Cancers

January 3, 2017

Critical Outcome Technologies Awards Stock Options